CureVac
T├╝bingen
About CureVac
CureVac develops messenger RNA (mRNA) technology for a variety of medical applications. The company focuses on creating innovative therapies aimed at treating diseases, particularly in the field of oncology. CureVac's pipeline includes mRNA-based vaccines and treatments that target various types of cancer, enhancing the body's immune response. Additionally, the company explores mRNA applications for infectious diseases, aiming to provide solutions that address public health challenges. Through its research and development efforts, CureVac contributes to the advancement of mRNA as a transformative approach in medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $500K – $1M
- Total funding: $2.1B
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2023)
- Ticker: nasdaq:CVAC
- Website: curevac.com
- Phone: +49 7071 9883 - 0
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/curevac-18331 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.